Avenue Therapeutics, Inc. (NASDAQ:ATXI) Sees Large Growth in Short Interest

Avenue Therapeutics, Inc. (NASDAQ:ATXI) was the target of a significant increase in short interest during the month of January. As of January 15th, there was short interest totalling 80,600 shares, an increase of 258.2% from the December 31st total of 22,500 shares. Based on an average daily volume of 358,600 shares, the short-interest ratio is presently 0.2 days. Approximately 4.6% of the company’s shares are sold short.

Avenue Therapeutics Stock Up 3.0 %

Shares of ATXI stock traded up $0.04 during trading hours on Friday, reaching $1.36. 101,766 shares of the stock traded hands, compared to its average volume of 1,091,758. The firm has a market capitalization of $2.79 million, a PE ratio of 0.07 and a beta of -0.27. Avenue Therapeutics has a 1-year low of $1.26 and a 1-year high of $15.00. The business has a fifty day moving average price of $1.83 and a 200 day moving average price of $2.27.

Institutional Trading of Avenue Therapeutics

An institutional investor recently bought a new position in Avenue Therapeutics stock. Moss Adams Wealth Advisors LLC acquired a new position in shares of Avenue Therapeutics, Inc. (NASDAQ:ATXI) in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 11,000 shares of the company’s stock, valued at approximately $27,000. Moss Adams Wealth Advisors LLC owned 1.17% of Avenue Therapeutics at the end of the most recent quarter. 17.34% of the stock is currently owned by institutional investors and hedge funds.

About Avenue Therapeutics

Avenue Therapeutics, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of neurologic diseases. Its product candidates include AJ201, which is in a Phase 1b/2a clinical trial for the treatment of spinal and bulbar muscular atrophy; intravenous tramadol for the treatment of post-operative acute pain; and BAER-101 for the treatment of epilepsy and panic disorders.